Our findings argue for a down-regulation of cAMP signalling, most likely via the EP3 prostanoid receptor, as a hallmark of PGE2-driven CRC cell proliferation and provide a framework for future in vitro studies on the mechanism of action of prostaglandins on CRC cells. The gene discussed is PTGER3; the disease is colorectal carcinoma.